



VIRTUAL
FORMAT

18·19
February 2021
CET (Central Europe Time)

Innovation in Breast Cancer

iBC 2021

DIRECTOR

Miguel Martín
Hospital General Universitario Gregorio Marañón, Madrid

Innovation in Breast Cancer – iBC 2021

THURSDAY **18th** February 2021

FRIDAY **19th** February 2021

VIRTUAL
FORMAT

CET (Central Europe Time)

16:00-16:15

Introduction

Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

SESSION I: **CANCER BIOLOGY**

Chair: Luis Marqués da Costa, Hospital de Santa María, Lisbon, Portugal

16:15-16:45

Chronology of breast cancer metastases

Christina Curtis, Stanford University, California, USA

Discussion

16:45-17:15

Exercise and immunometabolic regulation in cáncer

Lee Jones, Memorial Sloan Kettering Cancer Center, New York, USA

Discussion

17:15-17:45

Mechanisms of resistance to CDK 4/6 inhibitors

Mitchell Dowsett, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK

Discussion

17:45-18:00

Break

SESSION II: **CANCER THERAPY**

Chair: José Enrique Alés, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain

18:00-18:30

Does axillary lymph node dissection improve survival of node-positive operable breast cancer in the 21st century?

Terry Mamounas, Orlando Health Cancer Institute, Orlando, USA

Discussion

18:30-19:00

Newly drugs in early HER2-positive breast cancer

Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Discussion

19:00-19:30

CDK 4/6 inhibitors in breast cancer: from the bench to the bedside

Richard Finn, University of California, Los Angeles, USA

Discussion

SESION III: **CANCER BIOMARKERS**

Chair: Joan Albanell, Hospital del Mar, Barcelona, Spain

16:00-16:30

ctDNA and circulating tumor cells as predictors of relapse after neoadjuvant therapy for triple negative breast cancer

Milan Radovich, Indiana University School of Medicine, Indianapolis, USA

Discussion

16:30-17:00

Artificial Intelligence as a tool for identifying breast cancer subtypes

Maggie Cheang, The Institute of Cancer Research, London, UK

Discussion

17:00-17:30

Are current assay approval policies accurate enough? Repercussion on clinical practice

Roberto Salgado, GZA-ZNA Hospitals, Antwerp, Belgium

Discussion

17:30-17:45

Break

SESSION IV: **CANCER THERAPY**

Chair: Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

17:45-18:15

Newly drugs in metastatic HER2-positive breast cancer

Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

Discussion

18:15-18:45

Adjuvant CDK 4/6 inhibitors in operable luminal breast cancer: facts and prospects

Stephen Johnston, The Royal Marsden NHS Foundation Trust, London, UK

Discussion

18:45-19:15

HER2-low: characterization and role as a biomarker and target of therapy

Frederique Penault-Llorca, Centre Jean Perrin - Université Clermont-Auvergne, Clermont-Ferrand, France

Discussion

19:25

Closing remarks

Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Innovation in Breast Cancer – iBC 2021

VIRTUAL
FORMAT

CET (Central Europe Time)

Sponsors

Platinum



Gold



Silver



Bronze



Other collaborations



Under the auspices of



Organized by



Accreditation

Continuing Education Credits requested to the Spanish National Health System

Symposium secretariat



Tel.: (+34) 91 372 02 03
e-mail: ibc@doctaforum.com
www.innovationinbreastcancer.com